Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
Executive SummaryThe year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior
You may also be interested in...
Launches in 2012 clearly reflect the changes in pharma’s R&D investment priorities in recent years, as the industry has shifted emphasis from primary-care blockbusters to more targeted specialty models. The group includes potential blockbusters like Xeljanz, a dozen novel oncologics, the first new obesity drug in over a decade, and several treatments for rare diseases.